Share Email Print

Proceedings Paper

Novel liposomal combination treatments using dual genes knockdown in oral cancer treatment
Author(s): Jyun-Sian Wu; Chia-Hsien Yeh ; Leaf Huang; Yih-Chih Hsu
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Small interfering RNA (siRNA) can be used to treat tumor because it can effectively knockdown target oncoprotein expression and it leads to cancer cell death and apoptosis. Hypoxia-inducible factors-1 (HIF-1) is a transcription factor gene. Its high expression of tumor hypoxia cells, activation of transcription factor HIF-1α and angiogenesis found in most cancerous tissues. HIF-1α protein in cancer cells are critical to cell survival, tumor growth and proliferation. Epidermal growth factor receptor (EGFR) gene is another common head and neck oncogene. The dual self-designed siRNA sequences were encapsulated in the lipid-calcium-phosphate (LCP) and targeted to sigma receptors on the surface of cancer cells via binding to amino ethyl anisamide (AEAA). We used human oral cancer cells to establish the xenograft animal model to study the combination therapy for therapeutic results.

Paper Details

Date Published: 19 February 2018
PDF: 5 pages
Proc. SPIE 10495, Biophotonics and Immune Responses XIII, 1049512 (19 February 2018); doi: 10.1117/12.2291740
Show Author Affiliations
Jyun-Sian Wu, Chung Yuan Christian Univ. (Taiwan)
Chia-Hsien Yeh , Chung Yuan Christian Univ. (Taiwan)
Leaf Huang, Chung Yuan Christian Univ. (United States)
Univ. of North Carolina at Chapel Hill (United States)
Yih-Chih Hsu, Chung Yuan Christian Univ. (Taiwan)

Published in SPIE Proceedings Vol. 10495:
Biophotonics and Immune Responses XIII
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top